Bellevue Group Ag Celldex Therapeutics, Inc. Transaction History
Bellevue Group Ag
- $6.38 Billion
- Q1 2024
A detailed history of Bellevue Group Ag transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 2,796,615 shares of CLDX stock, worth $93.1 Million. This represents 1.84% of its overall portfolio holdings.
Number of Shares
2,796,615
Previous 2,416,296
15.74%
Holding current value
$93.1 Million
Previous $95.8 Million
22.48%
% of portfolio
1.84%
Previous 1.49%
Shares
5 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
61.2MCall Options Held
291KPut Options Held
246K-
Wellington Management Group LLP Boston, MA7.65MShares$255 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.51MShares$150 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.65MShares$122 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.12MShares$104 Million2.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$103 Million0.02% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.56B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...